Genmab A/S (GMAB)

NASDAQ: GMAB · IEX Real-Time Price · USD
36.08
-0.41 (-1.12%)
At close: Sep 22, 2023, 4:00 PM
35.90
-0.18 (-0.50%)
Pre-market: Sep 25, 2023, 7:45 AM EDT
-1.12%
Market Cap 23.56B
Revenue (ttm) 2.39B
Net Income (ttm) 693.28M
Shares Out 653.13M
EPS (ttm) 1.03
PE Ratio 37.63
Forward PE 35.34
Dividend n/a
Ex-Dividend Date n/a
Volume 1,255
Open 36.24
Previous Close 36.49
Day's Range 35.98 - 36.42
52-Week Range 31.40 - 47.50
Beta 0.66
Analysts Buy
Price Target 43.00 (+19.18%)
Earnings Date Nov 8, 2023

About GMAB

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL a... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1999
Employees 1,660
Stock Exchange NASDAQ
Ticker Symbol GMAB
Full Company Profile

Financial Performance

In 2022, Genmab's revenue was 14.60 billion, an increase of 72.07% compared to the previous year's 8.48 billion. Earnings were 5.52 billion, an increase of 83.58%.

Financial numbers in DKK Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for GMAB stock is "Buy." The 12-month stock price forecast is $43.0, which is an increase of 19.18% from the latest price.

Price Target
$43.0
(19.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Capital Increase in Genmab as a Result of Employee Warrant Exercise

Company Announcement COPENHAGEN, Denmark; September 12, 2023 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,356 shares as a consequence of the exercise of employee warrants.  The in...

12 days ago - GlobeNewsWire

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical ...

Other symbols: SGENZLAB
20 days ago - Market Watch

Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall sur...

Other symbols: SGEN
20 days ago - Reuters

Seagen and Genmab Announce TIVDAK® (tisotumab vedotin-tftv) Improved Overall Survival in Patients With Recurrent or Metastatic Cervical Cancer Compared With Chemotherapy Alone

BOTHELL, Wash. & COPENHAGEN, Denmark--(BUSINESS WIRE)--Seagen Inc. (Nasdaq: SGEN) and Genmab A/S (Nasdaq: GMAB) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic ce...

Other symbols: SGEN
20 days ago - Business Wire

Genmab and Seagen Announce That TIVDAK® (tisotumab vedotin-tftv) Met its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

COPENHAGEN, Denmark & BOTHELL, Wash.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Seagen Inc. (Nasdaq: SGEN) announced today that the Phase 3 innovaTV 301 global trial in recurrent or metastatic ce...

Other symbols: SGEN
20 days ago - Business Wire

Genmab to Present at Morgan Stanley 21st Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; August 28, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will p...

27 days ago - GlobeNewsWire

Genmab Announces Financial Results for the First Half of 2023

August 3 , 202 3 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2023

7 weeks ago - GlobeNewsWire

Genmab Updates 2023 Financial Guidance

Company Announcement COPENHAGEN , Denmark; July 2 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today its preliminary first half 2023 financial results and its updated 2023 financial guidance. Pr...

2 months ago - GlobeNewsWire

Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive ...

2 months ago - Business Wire

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023

Company Announcement Net sales of DARZALEX ® in the second quarter of 202 3 totaled USD 2,431 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, ...

2 months ago - GlobeNewsWire

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

-  Based on the topline results of epcoritamab from the EPCORE™ NHL-1 clinical trial, AbbVie and Genmab will engage global regulatory authorities to discuss next steps -  Additional data from the clin...

Other symbols: ABBV
3 months ago - PRNewsWire

Genmab and AbbVie Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody® CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) today announced topline results from the follicular lymphoma (FL) cohort of the phase 1/2 EPCORE™ NHL-1 clinical...

Other symbols: ABBV
3 months ago - Business Wire

Genmab Announces Epcoritamab Added to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for ‘B-Cell Lymphomas'

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that epcoritamab, a T-cell engaging bispecific antibody, has been added to the National Comprehensive Cancer Network® (N...

3 months ago - Business Wire

Genmab Showcases Data From Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas at European Hematology Association (EHA) Annual Meeting 2023

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced data from its ongoing phase 1/2 EPCORE™ NHL-2 trial investigating epcoritamab, a T-cell engaging bispecific antibody adm...

3 months ago - Business Wire

Grant of Restricted Stock Units and Warrants to Employees in Genmab

Company Announcement COPENHAGEN , Denmark; June 8 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today that the B oard decided to grant 7,825 restricted stock units and 8,106 warrants to employees o...

3 months ago - GlobeNewsWire

Genmab to Participate in a Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; June 6, 2023 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Goldman Sachs 44 th...

3 months ago - GlobeNewsWire

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement COPENHAGEN, Denmark; June 1, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this d...

4 months ago - GlobeNewsWire

Transactions with Shares and Linked Securities in Genmab A/S Made By Managerial Employees and Their Closely Associated Persons

Company Announcement COPENHAGEN, Denmark; May 31, 2023 – Genmab A/S (Nasdaq: GMAB) In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this d...

4 months ago - GlobeNewsWire

Genmab Announces Multiple Abstracts to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress

Genmab A/S (Nasdaq: GMAB) announced today that multiple abstracts evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, will be presented at the 2023 American Soci...

4 months ago - GlobeNewsWire

US FDA approves Genmab-AbbVie's blood cancer therapy

The U.S. Food and Drug Administration has approved AbbVie Inc and Danish drugmaker Genmab's experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment...

Other symbols: ABBV
4 months ago - Reuters

EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY™ (epcoritamab-bysp) as the first and only T-cell e...

4 months ago - Business Wire

Genmab Announces Financial Results for the First Quarter of 2023

May 10 , 202 3 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2023

4 months ago - GlobeNewsWire

Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen

Company Announcement C OPENHAGEN , Denmark; April 24 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today its decision to file a request for review of the award dismissing its claims in the second a...

5 months ago - GlobeNewsWire

Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen

Company Announcement COPENHAGEN , Denmark; April 21 , 20 2 3 – Genmab A/S ( Nasdaq: GMAB) announced today an award in the second arbitration arising under its license agreement with Janssen Biotech, ...

5 months ago - GlobeNewsWire

Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023

Company Announcement Net sales of DARZALEX ® in the first quarter of 202 3 totaled USD 2,264 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, D...

5 months ago - GlobeNewsWire